Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting

• Published in: Cancer chemotherapy and pharmacology Vol. 84; no. 1; pp. 147 - 153
• Main Authors: Tanaka, Kazuki, Inui, Naoki, Karayama, Masato, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Kusagaya, Hideki, Matsuura, Shun, Uto, Tomohiro, Hashimoto, Dai, Matsui, Takashi, Asada, Kazuhiro, Suda, Takafumi
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2019; Springer Nature B.V
• Subjects: Aged; Aged, 80 and over; Antiemetics; Antiemetics - administration & dosage; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antipsychotics; Aprepitant - administration & dosage; Cancer Research; Carboplatin; Carboplatin - administration & dosage; Carboplatin - adverse effects; Chemotherapy; Confidence intervals; Dexamethasone; Dexamethasone - administration & dosage; Drug Therapy, Combination; Female; Humans; Lung cancer; Lung Neoplasms - drug therapy; Male; Medicine; Medicine & Public Health; Middle Aged; Nausea; Nausea - chemically induced; Nausea - prevention & control; Neurokinin; Neurokinin NK1 receptors; Neurotransmitter receptors; Olanzapine; Olanzapine - administration & dosage; Oncology; Original Article; Pharmacology/Toxicology; Phase control; Prevention; Prospective Studies; Receiving; Receptors; Response rates; Serotonin; Serotonin S3 receptors; Vomiting; Vomiting - chemically induced; Vomiting - prevention & control; Carboplatin; Olanzapine; Antiemetic; Chemotherapy-induced nausea and vomiting

Purpose There remains an unmet clinical need for the control of chemotherapy-induced nausea and vomiting (CINV), particularly in the prevention of nausea and the delayed phase control. We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist, a 5...